Recent News

• 02.11.2025 - Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
• 02.10.2025 - Oncocyte Prices $29.1 Million Equity Offering
• 02.10.2025 - Oncocyte Prices $29.1 Million Equity Offering
• 01.08.2025 - Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer
• 01.06.2025 - Oncocyte Expands Market Opportunity for VitaGraft™ Kidney
• 01.06.2025 - Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Recent Filings

• 02.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.10.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.10.2025 - EX-99.1 EX-99.1
• 02.10.2025 - 8-K Current report
• 02.10.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.15.2025 - 4 Statement of changes in beneficial ownership of securities